A new approach to residual risk in treated hypertension-3P screening

Hypertension

Volumn 62, Issue 2, 2013, Pages 236-239

  Struthers, Allan D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ATORVASTATIN; BRAIN NATRIURETIC PEPTIDE; CHOLESTEROL; CREATININE; LISINOPRIL; TROPONIN T;

AGED; AIR POLLUTION; ANGIOPLASTY; ANTIHYPERTENSIVE THERAPY; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE; CANCER SCREENING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CASE REPORT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DRUG DOSE INCREASE; ECHOCARDIOGRAPHY; EXERCISE TEST; FALSE NEGATIVE RESULT; GLOMERULUS FILTRATION RATE; HEART ATRIUM ENLARGEMENT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MALE; MICROALBUMINURIA; PASSIVE SMOKING; PERSONALIZED MEDICINE; PRIMARY PREVENTION; PRIORITY JOURNAL; PULSE WAVE; RADIATION EXPOSURE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SILENT MYOCARDIAL ISCHEMIA; SOCIAL ISOLATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SUDDEN CARDIAC DEATH; TOMOGRAPHY;

CARDIAC ARRHYTHMIA; HYPERTENSION; RISK;

AGED; BIOLOGICAL MARKERS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INDIVIDUALIZED MEDICINE; MALE; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84880959250     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.01586     Document Type: Article

References (27)

1. Blacher J, Evans A, Arveiler D, Amouyel P, Ferrieres J, Bingham A, Yarnell J, Haas B, Montaye M, Ruidavets JB, Ducimetiere P. Residual cardiovascular risk in treated hypertension and hyperlipidaemia: the PRIME Study. J Hum Hypertens. 2010;24:19-26.
2. Andersson OK, Almgren T, Persson B, Samuelsson O, Hedner T, Wilhelmsen L. Survival in treated hypertension: follow up study after two decades. BMJ. 1998;317:167-171.
3. Glynn RJ, L'Italien GJ, Sesso HD, Jackson EA, Buring JE. Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure. Hypertension. 2002;39:105-110.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486-2497.
5. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-753.
6. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335:136.
7. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlöv J. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107-2116.
8. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-1585.
9. Vamos EP, Harris M, Millett C, Pape UJ, Khunti K, Curcin V, Molokhia M, Majeed A. Association of systolic and diastolic blood pressure and all cause mortality in people with newly diagnosed type 2 diabetes: retrospective cohort study. BMJ. 2012;345:e5567.
10. Nadir MA, Rekhraj S, Wei L, Lim TK, Davidson J, MacDonald TM, Lang CC, Dow E, Struthers AD. Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease. J Am Coll Cardiol. 2012;60:960-968.
11. Krahwinkel W, Ketteler T, Gödke J, Wolfertz J, Ulbricht LJ, Krakau I, Gülker H. Dobutamine stress echocardiography. Eur Heart J. 1997;18(suppl D):9-15.
12. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996;335:1107-1114.
13. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456-2467.
14. Simpson HJ, Gandy SJ, Houston JG, Rajendra NS, Davies JI, Struthers AD. Left ventricular hypertrophy: reduction of blood pressure already in the normal range further regresses left ventricular mass. Heart. 2010;96:148-152.
15. Tsang TS, Barnes ME, Gersh BJ, Takemoto Y, Rosales AG, Bailey KR, Seward JB. Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. J Am Coll Cardiol. 2003;42:1199-1205.
16. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, van Ree JW, Daemen MJ, Houben LG, Wellens HJ. Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol. 1997;30: 1500-1505.
17. Paget V, Legedz L, Gaudebout N, Girerd N, Bricca G, Milon H, Vincent M, Lantelme P. N-terminal pro-brain natriuretic peptide: a powerful predictor of mortality in hypertension. Hypertension. 2011;57:702-709.
18. Erne P, Schoenenberger AW, Zuber M, Burckhardt D, Kiowski W, Dubach P, Resink T, Pfisterer M. Effects of anti-ischaemic drug therapy in silent myocardial ischaemia type I: the Swiss Interventional Study on Silent Ischaemia type I (SWISSI I): a randomized, controlled pilot study. Eur Heart J. 2007;28:2110-2117.
19. Sorajja P, Chareonthaitawee P, Rajagopalan N, Miller TD, Frye RL, Hodge DO, Gibbons RJ. Improved survival in asymptomatic diabetic patients with high-risk SPECT imaging treated with coronary artery bypass grafting. Circulation. 2005;112(9 suppl):I311-I316.
20. Erne P, Schoenenberger AW, Burckhardt D, Zuber M, Kiowski W, Buser PT, Dubach P, Resink TJ, Pfisterer M. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA. 2007;297:1985-1991.
21. Kao MP, Ang DS, Gandy SJ, Nadir MA, Houston JG, Lang CC, Struthers AD. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol. 2011;22:1382-1389.
22. Rekhraj S, Gandy SJ, Szwejkowski BR, Nadir MA, Noman A, Houston JG, Lang CC, George J, Struthers AD. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol. 2013;61:926-932.
23. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
24. Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H, Vincent J, Pitt B. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol. 2012;59:1598-1603.
25. Pauriah M, Khan F, Lim TK, Elder DH, Godfrey V, Kennedy G, Belch JJF, Booth NA, Struthers AD, Lang CC. B-type natriuretic peptide is an independent predictor of endothelial function in man. Clinical Science. 2012;123:307-312.
26. Kavousi M, Elias-Smale S, Rutten JH, et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med. 2012;156:438-444.
27. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631-2639.